Soraprazan - Katairo
Alternative Names: BY-359; BYK-61359; RemofuscinLatest Information Update: 28 Jun 2022
At a glance
- Originator ALTANA Pharma
- Developer ALTANA Pharma; Katairo
- Class Antiulcers; Eye disorder therapies; Imidazoles; Naphthyridines
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Stargardt disease
- No development reported Dry age-related macular degeneration
- Discontinued Gastro-oesophageal reflux
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for phase-I development in Dry age-related macular degeneration in Germany (PO, Tablet)
- 30 May 2019 Phase-I clinical trials in Dry age-related macular degeneration in Germany (PO) (Katairo Pipeline, May 2019)
- 09 May 2019 Phase-II clinical trials in Stargardt disease in United Kingdom, Italy, Germany (PO) (EudraCT2018-001496-20)